What should investors who are experiencing Nasdaq market whiplash do now? Alphabet is now quite reasonably valued with a price-to-earnings-to-growth (PEG) ratio of 1.04, based on data from LSEG.

Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is ...

The opioid crisis has claimed the lives of over half a million Americans since the beginning of the epidemic, a process ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...

FDA Approves New-Age NON-OPIOID Pain Relief Formula That Does NOT Shut Down Your Vital Organs Via Heroin Addiction. NEWS ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Recent developments have solidified the company’s innovative edge, including the FDA approval of JOURNAVX in January 2025, a major leap in non-opioid pain management treatments. The UK approval ...